86 results about "Sphincter muscle" patented technology

A method and apparatus for introducing a first elongate medical device and short wire guide that are coupled together into a work site and remotely disconnecting them within the work site such that a secondary device comprising a catheter member can be introduced over the wire guide to the work site, and / or a second wire guide can be introduced to the work site via a passageway of the primary access device. A system of indicia, such as radiopaque or viewable markers, permit the operator to monitor the relative alignment of the devices within the work site to determine when uncoupling has occurred. In one example of the method, a wire guide and primary access device (e.g., a sphincterotome) is coupled to the wire guide and introduced via a duodenoscope into the biliary system. After performing a first medical operation, the devices are uncoupled with the wire guide being left within the biliary system such that a secondary access device, such as a balloon, biopsy device, stent delivery catheter, dilator, etc., can be introduced to perform a second medical operation without a traditional over-the-wire exchange being required. In another example of the method, a prosthesis, such as a valve or stent, is placed within the work site coupled to a wire guide which is remotely disconnected within the work site and a secondary device, such as a dilation balloon or second prosthesis, is introduced into the work site after the first delivery system is removed.

A rod-like or tube-like sphincteric closure device is micro-invasively implanted beneath the surface of the posterior mucosal wall to elevate the mucosa and close the lumen, by using a delivery device operated through the urethra. To initiate voiding, the muscle-rich anterior urethral wall contracts and widens the lumen beyond the closing or elevating range of the sphincteric closure device. For urethral obstruction, repelling magnets are micro-invasively implanted beneath the surface of mucosa with the delivery device through the urethra, to widen the lumen with magnetic force.

Various obesity treatment tools and methods are described herein, as well as treatments for other gastric-related diseases, e.g., GERD. Treatment includes reducing the size of the stomach pouch to limit the caloric intake as well as to provide an earlier feeling of satiety. This may be done by creating a smaller gastric pouch within the stomach directly from the interior of the stomach itself. The smaller pouches may be made through the use of individual anchoring devices, rotating probes, or volume reduction devices. A pyloroplasty procedure may also be performed to render the pyloric sphincter incompetent. A gastric bypass procedure may additionally be performed using atraumatic magnetic anastomoses devices so that sugars and fats are passed directly to the bowel while bypassing the stomach. Many of these procedures may be done in a variety of combinations. Treatment may create enforced behavioral modifications by discouraging the ingestion of high-caloric foods.

A prostatic stent is configured as a unitary body, which is adapted to reside above the sphincter when in position in a subject and allow normal functioning of the sphincter. The stent includes and elongated and substantially narrow conduit, which extends through the sphincter and outside the body of the subject. The conduit is sized and constructed to allow normal operation of the sphincter. The stent also includes and upper and / or an intermediate inflatable portions and may include a second conduit for the introduction of medication to the stent.

The method of the invention includes accessing a juncture of an esophagus and a stomach of the patient on a distal side of a diaphragm. The esophagus and a fundus of the stomach intersect at a cardiac notch located at an original cardiac notch position. A reducing element is placed at the junction with the reducing element selected to reposition the cardiac notch to a position more distal to a lower esophageal sphincter of the patient.

An urethral drain having deep external drainage channels, a low-profiled bladder retention segment, and a reversibly detachable collection segment, facilitates the draining of urine and fluids from the bladder. The low-profiled retention means minimizes bladder irritations and the deep external channels reduce the occurrence of infections. Incorporation of a reduced diameter smooth segment on the catheter, proximate the location of the external urethral sphincter allows the patient to void normally and at will. Modifying the size of this smooth segment aids the function of a defective sphincter in controlling urine leakage. The drain can be worn concealed within the urethra. Flushing action from normal voiding washes out particulate matters in the urethra and the concealed drain further minimizes contamination. Together, these features improve quality of life for patients needing catheterization.

A biologically implantable artificial sphincter system and methods of using the same is disclosed. The artificial sphincter system disclosed herein comprises a support and an electroactive polymer element, both of which are adapted and configured to open and / or close a body cavity. The artificial sphincter systems are useful in the treatment of urinary incontinence, fecal incontinence, and reflux disorders. The implanted artificial sphincter can also provide a signal to the recipient to urinate or defecate.

There is disclosed a method for treating anal incontinence in women. The method comprises accessing the rectum or colon or anus though an incision in the vagina and implanting a powered restriction device on the rectum, colon or anal sphincter. There are also disclosed methods for energizing and controlling the restriction device.

An implantable device for the treatment of acid reflux disease has a body including an outer surface adapted to rest against a patient's fundus wall. The device, when implanted in a patient, fills a volume in the patient's abdomen in the cardia area and above the cardia of the patient, when standing. The body prevents the cardia from moving through the diaphragm opening into the thorax, thereby preventing reflux by keeping the abdominal pressure supporting the cardia sphincter muscle. The device may be affixed to stomach tissue. The device may also be invaginated or otherwise indirectly secured in position.

An apparatus for the treatment of acid reflux disease has an implantable movement restriction device adapted to be at least partly invaginated by a patient's stomach fundus wall. A substantial part of the outer surface of the movement restriction device is adapted to rest against the stomach wall without injuring the latter in a position between the patient's diaphragm and at least a portion of the lower part of the invaginated stomach fundus wall, such that movement of the cardiac notch of the patient's stomach towards the patient's diaphragm is restricted, to thereby prevent the cardia from sliding through the patient's diaphragm opening into the patient's thorax, so as to maintain the supporting pressure against the patient's cardia sphincter muscle exerted from the patient's abdomen. The movement restriction device has a size of at least 125 mm3 and a circumference of at least 15 mm.

The teachings are directed to an intragastric device comprising a flexible and expandable bladder having a predetermined shape upon expansion for contacting the antrum of the stomach of a subject. The device is designed to avoid passage of any part of the device beyond the pylorus and lower esophageal sphincter while the bladder is expanded during use. In these embodiments, the bladder can contain a high specific gravity material when expanded; wherein, the high specific gravity material contributes to an in vivo specific gravity of the device that ranges from about 1.2 g / ml to about 2.1 g / ml and functions to direct the device to the pyloric antrum of the subject during use of the device. Moreover, these embodiments can include a filling material comprising a biocompatible fluid component and a hydrogel component to make the device substantially leakproof and contribute to the in vivo specific gravity of the device.

An indwelling catheter is positioned in a urinary tract to drain urine from the bladder to a position distally adjacent to a sphincter muscle. A balloon of the catheter is inflated through an inflation tube extending through the urinary tract. A coiled section of the inflation tube contacts the constriction caused by the sphincter muscle. The balloon and the coiled section resist movement of the indwelling catheter while still permitting natural urination. The indwelling catheter is inserted by an insertion tool which is separably connected to the catheter. Once the indwelling catheter is positioned, the tool is disconnected and withdrawn from the urinary tract. Risks of blood clots obstructing the flow of urine through the indwelling catheter immediately following a surgical procedure on the prostate gland are avoided by flushing fluid through the insertion tool and the catheter to clear an internal urine flow passageway in the catheter.

A variety of passive intragastric implant devices for obesity treatment are disclosed. Such passive devices do not autonomously change shape, but instead react within the stomach to induce satiety. The devices may take up volume within the stomach, thus reducing the intake capacity. Additionally, the devices may contact areas within the stomach, such as the cardia surrounding the esophageal sphincter, or the greater and lesser curvatures in the middle of the stomach, to stimulate satiety-inducing nerves. Some devices may combine two or more of these satiety-inducing features. Methods of implant are disclosed including compressing the devices within a delivery tube and transorally advancing the devices through the esophagus to be deployed within the stomach. Removal of the devices occurs in the reverse.

Provided herein are methods for the treatment of bladder dysfunction, including detrusor hyperreflexia and detrusor external sphincter dyssynergia, fecal incontinence, and / or sexual dysfunction in an individual via the use of stably expressed light-responsive opsin proteins capable of selective hyperpolarization or depolarization of the neural cells that innervate the muscles responsible for physiologic functioning of urinary bladder, external urinary sphincter, external anal sphincter, and the male and female genitalia.

A variety of passive intragastric implant devices for obesity treatment are disclosed. Such passive devices may not autonomously change shape, but instead react within the stomach to induce satiety. The devices may provide slowed entry into the stomach, thus reducing the intake capacity. Additionally, the devices may contact areas within the stomach, such as the cardia surrounding the esophageal sphincter, to stimulate satiety-inducing nerves. Some devices combine two or more of these satiety-inducing features. Methods of implant are disclosed including compressing the devices within a delivery tube and transorally advancing the devices through the esophagus to be deployed within the stomach. Removal of the devices occurs in the reverse. The implants are formed of materials that permit the implant to be compressed into a substantially linear transoral delivery configuration and that will resist degradation over a period of at least six months within the stomach.

The invention relates to the field of medical instruments, and provides a multifunctional stomach tube and an initialization method for a pressure detection unit of the stomach tube. The stomach tube comprises a duct, a first channel for conveying nutrient solution is arranged in the duct and provided with a plurality of flow injection holes led to outside, the flow injection holes are formed in the conveying direction of the nutrient solution at intervals, an intraesophageal pH (potential of hydrogen) value detection unit, a temperature detection unit and the pressure detection unit are arranged outside the duct, a monitoring device comprises a main control module, an operator sets relevant parameters by the main control module, and the main control module is used for processing, displaying and recording data information acquired from detection units, 5cm position of upper portion of the lower esophageal sphincter and a pH value of the inside of the stomach are detected, crowds with aspiration risks can be rapidly identified, the temperature detection unit is additionally arranged on a nasopharyngeal area, so that clinical daily body temperature monitoring is facilitated, infected patients are timely found, pressure variation of air bags can be monitored through the pressure detection unit, so that intraesophageal pressure is reflected, and intrapleural pressure is further calculated.

A method and apparatus for minimizing fecal incontinence in a subject, is disclosed. An inhibition action incontinence device includes a truncated cone with an angled concavity at a top portion. The truncated cone is positioned at the external opening of the anal canal. The truncated cone may be positioned to effect a positive pressure on the external sphincter muscles and the anal slit across the peri-anal tissues. It is believed that the truncated cone exploits the voluntary inhibition action of the external sphincter muscles and the simple mechanical closure of the anal slit to decrease fecal incontinence and soiling.

The invention discloses a method of regulating a stimulation frequency of a sacral nerve stimulator. The method comprises steps: two groups of stimulation electrodes are set; a stimulation changing period is set, wherein the stimulation changing period is a changing value; low-frequency impulses are transmitted to one stimulation electrode group and high-frequency impulses are transmitted to the other stimulation electrode group until the stimulation changing period is reached; in a next stimulation changing period, stimulation frequency signals of the two groups of stimulation electrodes are exchanged. The high-frequency and low-frequency combined electrical nerve stimulation is adopted to control contraction of bladder to empty the bladder, and generation of sphincter urethrae maladjusted contraction can also be avoided; the frequency amplitude in the low frequency part is changing, thereby avoiding fatigue on stimulation by nerve muscle; and only two stimulation points only need to be set, high-frequency and low-frequency stimulation is carried out alternatively at the two stimulation points, the problem of requiring multiple stimulation points is solved, and the operation difficulty is reduced.

The invention provides a system and a method of eliciting milk from all mammals that possess teats, including but not limited to dairy animals and humans. A system may be comprised of an elastic system and a vacuum supply. A method may include a milk elicitation system comprised of an elastic system and a vacuum supply. Through the application of vacuum, the elastic system forms, differentiates, seals and adapts to a teat, from the area it ends until up to where the udder ends and it begins, without coming in contact with the teat-end sphincter / lactiferous duct(s). The elastic system interacts proportionately according to the tendencies expressed by teat physiology and dynamics according to the milk pressure change, blood flow, and the effects of applied vacuum, throughout the milk elicitation process, resulting in continuous and complete milk elicitation and supporting the physiological teat return, after the process.

A bulking agent is accurately administered into body tissue surrounding the urethra of a patient to support a urinary sphincter muscle and facilitate enhanced control over urination. Preferably, the bulking agent is inserted by use of a catheter which is anchored with a balloon in the bladder. The balloon contacts the bladder neck and locates the position of a needle which is extended from the catheter into the tissue. Consequently, the bulking agent is injected at a position relative to the bladder neck which is very effective in supporting the sphincter muscle. The catheter is rotated in rotational increments to introduce the bulking agent in multiple positions in an annular ring surrounding the urethra.

The present invention relates to novel imidazole compounds having a positive allosteric GABAB receptor (CUR) modulator effect, methods for the preparation of said compounds and to their use, optionally in combination with a GABAB agonist, for the inhibition of transient lower esophageal sphincter relaxations, for the treatment of gastroesophageal reflux disease, as well as for the treatment of functional gastrointestinal disorders and irritable bowel syndrome (IBS).

A method for preventing and / or treating a functional gastrointestinal disorder, comprising administering, to a subject with the functional gastrointestinal disorder, rifaximin as an effective ingredient. The functional gastroinstestinal disorder includes a functional esophageal disorder, a functional gastroduodenal disorder (e.g., a functional dyspepsia), a functional bowel disorder (e.g., a functional bloating, a functional diarrhea), a functional abdominal pain syndrome, a functional gallbladder and Sphincter of Oddi disorder, a functional anorectal disorder (e.g., a functional fecal incontinence, a functional anorectal pain, a functional defecation disorder), a functional disorder in neonates and toddlers (e.g., an infant functional diarrhea), a functional disorder in children and adolescents (e.g., a childhood functional abdominal pain, a childhood nonretentive fecal incontinence), and other diseases.

Since a compound represented by formula (I) wherein all of the symbols are the same as defined in the specification, a salt thereof, a solvate thereof, a prodrug thereof, a mixture with a diastereomer thereof in an arbitrary ratio, or a cyclodextrin clathrate thereof have a contracting activity of bladder detrusor and a relaxing activity of urethral sphincter, they can ameliorate bladder contraction dysfunction and / or urethral relaxation dysfunction, and for example, are effective for underactive bladder. Additionally, the compound of the present invention has little risk of side effects on the urinary system, the circulatory system and the digestive system, and exhibits excellent pharmacokinetics, such as oral absorbability etc. Therefore, the compound of the present invention is useful as a superior agent for preventing, treating and / or ameliorating underactive bladder.

The present invention provides systems and methods for treating and controlling obesity and / or type II diabetes. In one aspect of the invention, an internal bypass device includes gastric and duodenal anchors coupled to each other and positioned on either side of the pylorus and a hollow sleeve designed to extend from the pylorus through at least a proximal portion of a patient's small intestine. The gastric and duodenal anchors are movable between collapsed configurations for advancement through the esophagus and an expanded configuration for inhibiting movement of the anchors through the pyloric sphincter. Thus, the bypass device can be placed and removed endoscopically through the patient's esophagus in a minimally invasive outpatient procedure and it is “self-anchoring” and does not require invasive tissue fixation within the patient's GI tract, thereby reducing collateral tissue damage and minimizing its impact on the digestive process.

The present invention relates to a cell therapy product which is intended for regenerating a sphincter muscle and which contains stem cells derived from amniotic fluid, and more particularly, to a cell therapy product which is intended for regenerating the sphincter vesicae and which contains stem cells derived from amniotic fluid. Also, the cell therapy product of the present invention can be provided in the form of a formulation for administration through injection, said formulation being injected into a hydrogel complex to thereby improve the effects thereof. The composition including stem cells derived from amniotic fluid according to the present invention enables stem cells to be differentiated into muscles in the body of individual suffering from urinary incontinence by directly injecting the composition into the individual, thus effectively controlling urinary incontinence by recovering muscle functions. That is, the stem cells derived from amniotic fluid of the present invention are differentiated into muscles in-situ, and the differentiation into muscles can thus be achieved only with cells in order to recover muscle functions.

The invention provides a system (500) and a method of eliciting milk from all mammals that possess teats, including but not limited to dairy animals and humans. A system (500) may be comprised of an elastic system (100) and a vacuum supply (200). A method may include a milk elicitation system (500) comprised of an elastic system (1OO) and a vacuum supply (200). Through the application of vacuum, the elastic system (100) forms, differentiates, seals and adapts to a teat, from the area it ends until up to where the udder ends and it begins, without coming in contact with the teat-end sphincter / lactiferous duct(s). The elastic system (100) interacts proportionately according to the tendencies expressed by teat physiology and dynamics according to the milk pressure change, blood flow, and the effects of applied vacuum, throughout the milk elicitation process, resulting in continuous and complete milk elicitation and supporting the physiological teat return, after the process.

The invention relates to a medicament for treating uracratia and a preparation method thereof. The medicament is prepared from raw radix astragalis, bighead atractylodes rhizome, parasitic loranthus, teasel, cornus, calcined fossil fragments, calcined oyster, sevenlobed yam rhizome and prepared liquorice root through compatibility, can raise yang, tonify liver and kidney and strengthen bones and muscles, invigorate spleen and supplement qi, benefit qi and nourish yin, strengthen lumbus and knees and reinforce body immunity, can remove dampness and reinforce dryness, eliminate dampness and induce diuresis, eliminate wind-damp, dredge collaterals, promote blood circulation for diminishing swelling, prevent miscarriage and nourish blood, stop bleeding and astringe intestine, relieve soreness and pain, soften hardness to dissipate stagnation, accelerate blood circulation, dispel wind evil and remove dampness, moisten the lungs and detoxify, diminish inflammation and relieve pain, reduce or retard influence of other diseases on uracratia and induce diuresis and promote micturition, can relieve convulsion and calm the nerves, constrain yin for hidroschesis, strengthen exterior and reducing sweat, arrest sweating for securing essence, astringe for induce astringency, regulate and restrain constriction and extension of sphincter vesicae and treat frequent micturition. The medicament disclosed by the invention can reinforce immunity of a patient, reduce or retard influence of other diseases on uracratia, accelerate blood circulation and micturition, strengthen control of the sphincter vesicae and has an obvious curative effect of treating uracratia.

The invention discloses a compound lidocaine aerosol and a preparation method thereof. The compound lidocaine aerosol comprises the following components in parts by weight: 0.2-3.5 parts of lidocaine,0.2-3.5 parts of propylamine caine, 1-3.5 parts of 0.1 M sodium hydroxide, 2-35 parts of propellant, 1-17.6 parts of polyvinyl alcohol and 0.1-1.75 parts of rutin derivative. Under the condition of not containing penetrant and surfactant components, lidocaine and propylamine caine in a basic group form are released to the subcutaneous layer, and polyvinyl alcohol is used for forming a film on thesurface of the skin, so that the dosage of lidocaine and propylamine caine is reduced, and the safety of clinical use is enhanced; the treatment of male premature ejaculation is mainly used for inhibiting the expansion of the minor artery and capillary anterior sphincter of the cavernous body of the penis, so that the smooth muscle is relaxed, and the blood flow volume is increased; the rutin derivative is added, the elasticity and permeability of the drug are improved by improving the capillary function, and adverse reactions such as vascular bleeding caused by long-term use of traditional lidocaine drugs are avoided.

The invention belongs to the technical field of haemorrhoids treatment, and discloses a medicament for treating haemorrhoids. The medicament is prepared from, by mass, 3-5 parts of ozonized oil, 1-3 parts of rhizoma bletillae extracts, 1-3 parts of sophora fruit extracts and 1-3 parts of radix saposhnikoviae extracts. The invention further provides a preparation method of the medicament for treating the haemorrhoids. The medicament has the effects of quickly diminishing inflammation, killing bacteria, relieving pain and stop bleeding, the perianal sphincter muscle can be effectively made to contract, and recurrence of the hemorrhoids can be prevented while the hemorrhoids is treated.